Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315

NCT00474552 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: SAM-315

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer